



Exeltis US will distribute benznidazole for the treatment of Chagas disease in patients aged 2-12 years old

Thursday, August 31, 2017

Exeltis US of New Jersey is delighted to announce that they will distribute benznidazole for the treatment of Chagas disease in patients aged 2-12 years old, in the United States following the approval by the FDA on the 29th of August 2017. The approval was secured by the Chemo Research team of the Chemo Group, the parent company of Exeltis Pharmaceuticals, in collaboration with Mundo Sano, DNDi and wide range of skilled and passionate specialists and advisors.

Exeltis will focus on ensuring accessibility and affordability to all patients in the US between 2-12 years that need treatment for Chagas Disease.

'This is a proud moment for our Company and we are excited to have the chance to make a difference to Chagas patients across the United States'- said Fernando Mateus - President of Exeltis US.

Chemo Group

Chemo Group is a global pharmaceutical company with over 40 years of experience and commitment in safeguarding and improving people's health and well-being. The Chemo Group has offices in more than 40 countries in Europe, the Americas, Asia, and Africa, and employs more than 6,000 professionals. The Group's 15 factories, 10 R&D centers, and 33 affiliated pharmaceutical companies provide high quality, accessible medicines and services to patients around the world while collaborating with more than 1150 pharmaceutical business partners in 96 countries. Chemo Research based in Spain and Madrid has played a central role in bringing benznidazole to the FDA for assessment and approval www.chemogroup.com (<http://www.chemogroup.com/>)

Exeltis

Exeltis is a branded pharmaceutical division of the Chemo Group that specializes in Women's Healthcare, Dermatology, Respiratory Disease and diseases of the Central Nervous System. Exeltis USA is located in New Jersey and is the market leader in PreNatal Vitamins and has a consolidated position in Women's Healthcare and Dermatology. Exeltis USA will use its operational and technical platform to support the availability of benznidazole in the United States in support of Mundo Sano - to help minimize costs and ensure compliance with FDA regulations. <http://exeltisusa.com/> (<http://exeltisusa.com/>)

Mundo Sano

Mundo Sano is a nonprofit foundation whose vision is the transformation of the realities of the populations affected by neglected tropical diseases since 1993. In pursuit of achieving greater equity, the institution works alongside the public and private sectors, academia, and other international organizations. In order to provide solutions to the affected communities and generate scientific knowledge, Mundo Sano led a public-private consortium in 2012 to produce benznidazole in Argentina, one of the two drugs that treat Chagas disease.

www.mundosano.org (<http://www.mundosano.org/>)

DNDi

A not-for-profit R&D organization, DNDi works to deliver new treatments for neglected tropical diseases. DNDi is actively engaged in developing new treatments and screening new compounds for Chagas disease. DNDi and partners delivered the first pediatric dosage form of benznidazole and are running clinical trials evaluating new regimens or combinations of the drug. DNDi is also involved in early stage research for entirely new drugs for Chagas disease.

www.dndi.org (<http://www.dndi.org/>)